Article Text

PDF
THU0096 Targeting Lymphatic Dysfunction in Rheumatoid Arthritis by High-Density Lipoprotein
  1. R. Bisoendial1,2,
  2. B. Roediger1,
  3. R. Jain1,
  4. L. Cavanagh1,
  5. P.-P. Tak3,4,
  6. K.-A. Rye5,
  7. W. Weninger1,6,7
  1. 1Immune Imaging, The Centenary Institute, Newtown, Sydney
  2. 2Lipid Research Group, Centre of Vascular Research, University of New South Wales, Kensington, Sydney, Australia
  3. 3Glaxo-Smith Kline, Brentford, London, United Kingdom
  4. 4Clinical Immunology and Rheumatology, Academic Medical Centre, Amsterdam, Netherlands
  5. 5Lipid Research Group, Centre for Vascular Research, University of New South Wales, Kensington, Sydney
  6. 6University of Sydney, Sydney
  7. 7Dermatology, Royal Prince Alfred Hospital, Camperdown, Sydney, Australia

Abstract

Background Rheumatoid arthritis (RA) is increasingly recognized to raise cardiovascular (CV) risk by two-fold. Our peliminary in vitro findings suggest that high-density lipoprotein (HDL) and its main apolipoprotein (apo)A-I may correct lymphatic dysfunction, a hallmark of chronic inflammation.

Objectives The impact of an i.v. injection of human apoA-I (40 mg/kg) or reconstituted (r)HDL - consisting of phosphatidylcholine with apoA-I - was evaluated on key lymphatic properties and resolution of inflammation in an acute mouse ear skin inflammation model.

Methods Inflammation was induced by intra-dermal injection of 2.5 ug of lipopolysaccharide (LPS; O55:B5), in animals that had received apoA-I, rHDL or PBS 24 hrs earlier. Two days after LPS-injection, i.e. the peak of inflammation, ear swelling and erythema were scored. The auricular draining lymph node (DLN) was harvested for flow cytometry to assess changes in inflammatory cell migration. Alexa594-LPS was used to study LPS clearance from ear to DLN using an in vivo imaging system (IVIS). Lymph flow from ear skin to DLN was monitored 15 min after injecting 1.5 ul of TexasRed-Dextran (TXR-DX) at the inflammatory site using a stereomicroscope and IVIS.

Results Erythema and swelling upon LPS were not significantly affected by pre-treatment with rHDL or apoA-I (24.8% and 38.4% increase respectively, as compared to PBS 36.7%). After 48 hrs, the influx of inflammatory cells in the DLN was significantly reduced upon pretreatment with rHDL and apoA-I (absolute cell numbers per DLN: PBS: 1x107±2x106; rHDL: 2x106±4x105 and apoA-I: 5x106±1x106). Particularly the numbers of neutrophils (632.5±388.9 and 2610±1395 for rHDL and apoA-I, as compared to 16788±5340 for PBS) and CD11c+MHC-IIhigh migratory dendritic cells (DC; 4873±1820 and 20680±7005 for rHDL and apoA-I, as compared to 41170±9495 for PBS) were diminished (all p<0.05). Compositional changes of leukocytes in the peripheral blood and spleen were less remarkable. Intravital monitoring of ALEXA594-LPS using IVIS showed similar LPS disappearance from the ears after 24 hrs (decrease 66.2% and 51.8% for rHDL and apoA-I respectively, as compared to PBS 73%). In line, fluorescence intensity of ALEXA594-LPS in the DLN after 48 hrs seemed unaffected by pretreatment with rHDL and apoA-I. Lymphangiography using TXR-DX revealed that LPS resulted in dysmorphic patterning of lymphatic vessels and hyperpermeability, pointing to functional impairment. Pretreatment with apoA-I resulted in less pronounced hyperpermeability and higher fluorescence recovery of TXR-DX in the DLN.

Conclusions Lymphatic properties comprising lymph flow and inflammatory cell migration that includes neutrophils and migratory DCs, is suggested to improve upon prior systemic administration of HDL and apoA-I in this LPS-induced ear skin inflammation model. Awaiting further results that may clarify the involved mechanisms and outcomes in chronic inflammation models these data support therapeutic benefits of HDL-based approaches in RA by targeting lymphatic dysfunction and thereby reducing CV risk.

Disclosure of Interest None Declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.